PT  - JOURNAL ARTICLE
AU  - Negri, Elnara Marcia
AU  - Piloto, Bruna Mamprim
AU  - Morinaga, Luciana Kato
AU  - Poyares Jardim, Carlos Viana
AU  - El-Dash Lamy, Shari Anne
AU  - Ferreira, Marcelo Alves
AU  - D’Amico, Elbio Antonio
AU  - Deheinzelin, Daniel
TI  - Heparin therapy improving hypoxia in COVID-19 patients - a case series
AID  - 10.1101/2020.04.15.20067017
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.15.20067017
4099  - http://medrxiv.org/content/early/2020/04/30/2020.04.15.20067017.short
4100  - http://medrxiv.org/content/early/2020/04/30/2020.04.15.20067017.full
AB  - INTRODUCTION Elevated D-dimer is a predictor of severity and mortality in COVID-19 patients and heparin use during in-hospital stay has been associated with decreased mortality. COVID-19 patient autopsies have revealed thrombi in the microvasculature, suggesting intravascular coagulation as a prominent feature of organ failure in these patients. Interestingly, in COVID-19, pulmonary compliance is preserved despite severe hypoxemia corroborating the hypothesis that perfusion mismatch may play a significant role in the development of respiratory failure.METHODS We describe a series of 27 consecutive COVID-19 patients admitted to Sirio-Libanes Hospital in São Paulo-Brazil and treated with heparin in therapeutic doses tailored to clinical severity.RESULTS AND DISCUSSION PaO2/FiO2 ratio increased significantly over the 72 hours following the start of anticoagulation, from 254(±90) to 325(±80), p=0.013, and 81% of the patients were discharged home within a mean time of 11.4 (±7.9) days. Most mechanically ventilated patients (67%) were extubated within 12.5(± 5.7) days. There were no bleeding complications or fatal events.Even though this uncontrolled case series does not offer absolute proof of DIC as the underlying mechanism of respiratory failure in COVID-19, patient’s positive response to tailored dose heparinization contributes to the understanding of the pathophysiological mechanism of the disease and provides valuable information for the treatment of these very sick patients while we await the results of further prospective controlled studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis was a retrospective study based on medical records data with no funding needed.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be provided if requested. It contais confidential medical records.